Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - VistaGen Therapeutics reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
VistaGen Therapeutics announced earnings per share of $-0.080 on revenue of $-892.5K. Analysts polled by Investing.com EPS of $-0.070 on revenue of $340.03K.
VistaGen Therapeutics 's are down 53.92% and is trading at $0.130 , still down 94.56% from its 52 week high of $2.39 set on Friday, November 12, 2021.
VistaGen Therapeutics follows other major Healthcare sector earnings this month
VistaGen Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar